HIF

シグナル伝達経路

研究分野

阻害剤の選択性比較

カタログ番号	製品カタログ	溶解度(25°C)
カタログ番号	製品カタログ	水	DMSO	アルコール
S1233	2-Methoxyestradiol (2-MeOE2)	<1 mg/mL	60 mg/mL	<1 mg/mL
S8771	IDF-11774	<1 mg/mL	15 mg/mL	5 mg/mL
S7309	BAY 87-2243	<1 mg/mL	33 mg/mL	8 mg/mL
S7946	KC7F2	<1 mg/mL	100 mg/mL	<1 mg/mL
S7958	Lificiguat(YC-1)	<1 mg/mL	60 mg/mL	60 mg/mL
S8441	LW 6	<1 mg/mL	13 mg/mL	1 mg/mL
S7612	PX-478 2HCl	78 mg/mL	78 mg/mL	78 mg/mL
S1007	Roxadustat (FG-4592)	<1 mg/mL	70 mg/mL	<1 mg/mL
S2919	IOX2	<1 mg/mL	7 mg/mL	<1 mg/mL
S8138	Molidustat (BAY 85-3934)	<1 mg/mL	3 mg/mL	<1 mg/mL
S7979	FG-2216	<1 mg/mL	56 mg/mL	<1 mg/mL
S8171	Daprodustat (GSK1278863)	<1 mg/mL	10 mg/mL	<1 mg/mL
S8443	MK-8617	<1 mg/mL	20 mg/mL	1 mg/mL
S7483	DMOG	35 mg/mL	35 mg/mL	35 mg/mL

亜型選択性的な製品

HIF製品

All (14) HIF阻害剤(7) HIFモジュレータ(7) 新HIF製品

製品コード	製品説明	文献中Selleckの製品使用例	お客様のフィードバック
S1233	2-Methoxyestradiol (2-MeOE2) 2-Methoxyestradiol (2-MeOE2) depolymerizes microtubules and blocks HIF-1α nuclear accumulation and HIF-transcriptional activity. Phase 2.	Nucleic Acids Res, 2015, 10.1093/nar/gkv379 Mol Cell Endocrinol, 2018, 10.1016/j.mce.2018.05.002 Australas J Dermatol, 2015, 10.1111/ajd.12340	Pancreatic cancer cell lines (CFPAC-1 and BxPC-3) were treated with siHIF-1 and 2-ME and then evaluate the expression HIF-1α, CRT and P-eIF2α by Western blotting experiment.
S8771^新	IDF-11774 IDF-11774 is a hypoxia-inducible factor-1 (HIF-1) inhibitor. It reduces the HRE-luciferase activity of HIF-1α (IC50 = 3.65 μM) and blocks HIF-1α accumulation under hypoxia in HCT116 human colon cancer cells.
S7309	BAY 87-2243 BAY 87-2243 is a potent and selective hypoxia-inducible factor-1 (HIF-1) inhibitor. Phase 1.	Vascul Pharmacol, 2016, 10.1016/j.vph.2016.05.002 Pathol Oncol Res, 2016, 10.1007/s12253-016-0076-3 Oncotarget, 2016, 7(52):86313-86325	Cells were plated at low density, treated with the indicated compounds and scored for resistance. Abbreviations: osimertinib (Osi), phenformin (Phen), metformin (Met), buformin (Buf), BAY 87-2243 (BAY), oligomycin (Oligo).
S7946	KC7F2 KC7F2 is a selective HIF-1α transcription inhibitor with IC50 of 20 μM in a cell-based assay.	Stem Cell Res Ther, 2018, 9(1):280 Respir Physiol Neurobiol, 2018, 247:87-95	Western blot analysis showed that KC7F2 (10 nM) significantly decreased the expression of HIF-1α, p27 and flt-1, while KC7F2 (10 nM) elevated cyclin D1 and flk-1 levels after 24 h incubation compared with the 1% O2 condition.
S7958	Lificiguat(YC-1) YC-1 is an nitric oxide (NO)-independent activator of soluble guanylyl cyclase(sGC) and an inhibitor of Hypoxia-inducible factor-1alpha (HIF-1alpha).
S8441	LW 6 LW6 is a hypoxia-inducible factor 1(HIF) inhibitor which potently inhibits HIF-1α accumulation by degrading HIF-1α without affecting the HIF-1a mRNA levels during hypoxia. It inhibits hypoxia-induced HIF-1α transcription activity with IC50 of 2.64 μM in cell-based HRE-reporter gene assays.
S7612	PX-478 2HCl PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. Phase 1.	Theranostics, 2018, 8(3):610-626 Br J Pharmacol, 2017, 174(5):409-423 Am J Cancer Res, 2017, 7(5):1198-1212	Glucose uptake and lactate production were determined in H460 and A549 lung cancer cells in the presence of the HIF1α inhibitor, PX-478 (10 μM) (** p < 0.01)
S1007	Roxadustat (FG-4592) Roxadustat (FG-4592) is an HIF-α prolyl hydroxylase inhibitor in a cell-free assay, stabilizes HIF-2 and induces EPO production. Phase 3.	J Hepatol, 2014, 61(4):746-54 Chem Sci, 2017, 10.1039/C7SC02103H Cell Physiol Biochem, 2018, 46(6):2460-2470	Immunoblots showing dose-dependent HIF-1α stabilization in U2OS, HeLa and Hep3b (and HIF-2α) cells after 6 hours treatment with FG-4592.
S2919	IOX2 IOX2 is a potent inhibitor of HIF-1α prolyl hydroxylase-2 (PHD2) with IC50 of 21 nM in a cell-free assay, >100-fold selectivity over JMJD2A, JMJD2C, JMJD2E, JMJD3, or the 2OG oxygenase FIH.	Arch Toxicol, 2016, 90(5):1141-50 Arch Toxicol, 2015, 10.1007/s00204-015-1549-y Int J Low Extrem Wounds, 2015, 14(1):63-72	NHEK and NHDF are cultivated under normoxic (N) and hypoxic (H) conditions in the presence of IOX2 (50 μM), or vehicle control (DMSO). b HIF-1α levels are analyzed in cell extracts of NHEK (4 h) and NHDF (24 h) by immunoblotting with cellular β-actin as loading control. c Subcellular localization of HIF-1α is examined by immunoblotting analysis of HIF-1α in nuclear (Nu) and cytoplasmic (Cy) fractions with β-tubulin as cytosolic loading control.
S8138	Molidustat (BAY 85-3934) Molidustat (BAY 85-3934) is a potent hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor with IC50 of 480 nM, 280 nM, and 450 nM for PHD1, PHD2, and PHD, respectively. Phase 2.	Theranostics, 2017, 7(13):3293-3305	Western blot analysis of the indicated proteins after the treatment with BAY 85-394 (L).
S7979	FG-2216 FG-2216 is a potent, and orally active HIF prolyl 4-hydroxylase inhibitor with IC50 of 3.9 μM for PHD2. Phase 2.
S8171	Daprodustat (GSK1278863) Daprodustat (GSK1278863) is an orally administered hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor. Phase 2.
S8443	MK-8617 MK-8617 is an orally active pan-inhibitor of Hypoxia-inducible factor prolyl hydroxylase 1−3 (HIF PHD1−3), inhibiting PHD1, 2, 3 with IC50s of 1.0, 1.0 and 14 nM, respectively.
S7483	DMOG DMOG is an antagonist of α-ketoglutarate cofactor and inhibitor for HIF prolylhydroxylase.	Hepatology, 2018, 68(6):2359-2375 Theranostics, 2017, 7(13):3293-3305 J Cell Mol Med, 2018, 22(9):4507-4521	Western blot was performed to analyze p65 signaling and the expression of Bcl2 and cleaved Caspase 3. GAPDH served as the loading control

製品コード	製品説明	文献中Selleckの製品使用例	お客様のフィードバック
S1233	2-Methoxyestradiol (2-MeOE2) 2-Methoxyestradiol (2-MeOE2) depolymerizes microtubules and blocks HIF-1α nuclear accumulation and HIF-transcriptional activity. Phase 2.	Nucleic Acids Res, 2015, 10.1093/nar/gkv379 Mol Cell Endocrinol, 2018, 10.1016/j.mce.2018.05.002 Australas J Dermatol, 2015, 10.1111/ajd.12340	Pancreatic cancer cell lines (CFPAC-1 and BxPC-3) were treated with siHIF-1 and 2-ME and then evaluate the expression HIF-1α, CRT and P-eIF2α by Western blotting experiment.
S8771^新	IDF-11774 IDF-11774 is a hypoxia-inducible factor-1 (HIF-1) inhibitor. It reduces the HRE-luciferase activity of HIF-1α (IC50 = 3.65 μM) and blocks HIF-1α accumulation under hypoxia in HCT116 human colon cancer cells.
S7309	BAY 87-2243 BAY 87-2243 is a potent and selective hypoxia-inducible factor-1 (HIF-1) inhibitor. Phase 1.	Vascul Pharmacol, 2016, 10.1016/j.vph.2016.05.002 Pathol Oncol Res, 2016, 10.1007/s12253-016-0076-3 Oncotarget, 2016, 7(52):86313-86325	Cells were plated at low density, treated with the indicated compounds and scored for resistance. Abbreviations: osimertinib (Osi), phenformin (Phen), metformin (Met), buformin (Buf), BAY 87-2243 (BAY), oligomycin (Oligo).
S7946	KC7F2 KC7F2 is a selective HIF-1α transcription inhibitor with IC50 of 20 μM in a cell-based assay.	Stem Cell Res Ther, 2018, 9(1):280 Respir Physiol Neurobiol, 2018, 247:87-95	Western blot analysis showed that KC7F2 (10 nM) significantly decreased the expression of HIF-1α, p27 and flt-1, while KC7F2 (10 nM) elevated cyclin D1 and flk-1 levels after 24 h incubation compared with the 1% O2 condition.
S7958	Lificiguat(YC-1) YC-1 is an nitric oxide (NO)-independent activator of soluble guanylyl cyclase(sGC) and an inhibitor of Hypoxia-inducible factor-1alpha (HIF-1alpha).
S8441	LW 6 LW6 is a hypoxia-inducible factor 1(HIF) inhibitor which potently inhibits HIF-1α accumulation by degrading HIF-1α without affecting the HIF-1a mRNA levels during hypoxia. It inhibits hypoxia-induced HIF-1α transcription activity with IC50 of 2.64 μM in cell-based HRE-reporter gene assays.
S7612	PX-478 2HCl PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. Phase 1.	Theranostics, 2018, 8(3):610-626 Br J Pharmacol, 2017, 174(5):409-423 Am J Cancer Res, 2017, 7(5):1198-1212	Glucose uptake and lactate production were determined in H460 and A549 lung cancer cells in the presence of the HIF1α inhibitor, PX-478 (10 μM) (** p < 0.01)

製品コード	製品説明	文献中Selleckの製品使用例	お客様のフィードバック
S1007	Roxadustat (FG-4592) Roxadustat (FG-4592) is an HIF-α prolyl hydroxylase inhibitor in a cell-free assay, stabilizes HIF-2 and induces EPO production. Phase 3.	J Hepatol, 2014, 61(4):746-54 Chem Sci, 2017, 10.1039/C7SC02103H Cell Physiol Biochem, 2018, 46(6):2460-2470	Immunoblots showing dose-dependent HIF-1α stabilization in U2OS, HeLa and Hep3b (and HIF-2α) cells after 6 hours treatment with FG-4592.
S2919	IOX2 IOX2 is a potent inhibitor of HIF-1α prolyl hydroxylase-2 (PHD2) with IC50 of 21 nM in a cell-free assay, >100-fold selectivity over JMJD2A, JMJD2C, JMJD2E, JMJD3, or the 2OG oxygenase FIH.	Arch Toxicol, 2016, 90(5):1141-50 Arch Toxicol, 2015, 10.1007/s00204-015-1549-y Int J Low Extrem Wounds, 2015, 14(1):63-72	NHEK and NHDF are cultivated under normoxic (N) and hypoxic (H) conditions in the presence of IOX2 (50 μM), or vehicle control (DMSO). b HIF-1α levels are analyzed in cell extracts of NHEK (4 h) and NHDF (24 h) by immunoblotting with cellular β-actin as loading control. c Subcellular localization of HIF-1α is examined by immunoblotting analysis of HIF-1α in nuclear (Nu) and cytoplasmic (Cy) fractions with β-tubulin as cytosolic loading control.
S8138	Molidustat (BAY 85-3934) Molidustat (BAY 85-3934) is a potent hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor with IC50 of 480 nM, 280 nM, and 450 nM for PHD1, PHD2, and PHD, respectively. Phase 2.	Theranostics, 2017, 7(13):3293-3305	Western blot analysis of the indicated proteins after the treatment with BAY 85-394 (L).
S7979	FG-2216 FG-2216 is a potent, and orally active HIF prolyl 4-hydroxylase inhibitor with IC50 of 3.9 μM for PHD2. Phase 2.
S8171	Daprodustat (GSK1278863) Daprodustat (GSK1278863) is an orally administered hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor. Phase 2.
S8443	MK-8617 MK-8617 is an orally active pan-inhibitor of Hypoxia-inducible factor prolyl hydroxylase 1−3 (HIF PHD1−3), inhibiting PHD1, 2, 3 with IC50s of 1.0, 1.0 and 14 nM, respectively.
S7483	DMOG DMOG is an antagonist of α-ketoglutarate cofactor and inhibitor for HIF prolylhydroxylase.	Hepatology, 2018, 68(6):2359-2375 Theranostics, 2017, 7(13):3293-3305 J Cell Mol Med, 2018, 22(9):4507-4521	Western blot was performed to analyze p65 signaling and the expression of Bcl2 and cleaved Caspase 3. GAPDH served as the loading control

Tags: HIF pathway | HIF cancer | hypoxia-inducible factor cancer | HIF-1 cancer | HIF activation | HIF-1 pathway | hypoxia-inducible factor pathway | HIF-1 activation | HIF-1α pathway | HIF inhibitor review

Download catalog

サイトマップ

注文する方法

Pharmacological Glossary

モル濃度計算器

希釈計算器

分子量計算器

輸送温度 :冷凍（-15℃—-20℃）
お薦めの保存温度 : -20℃以下

Products are for research use only. Not for human use. We do not sell to patients.

全部無料で郵便にて送ります

東京都以内の郵便は当日に届けられます。東京都以外「伊豆諸島、小笠原諸島、沖縄及び北海道等の辺鄙地域を除く」の郵便は翌日に届けられます。

×

大阪市内で「G20サミット」が開催されることに伴い、大阪府内で大規模な交通規制が行われる影響で、6月26日（水）から7月1日（月）までの間、下記地域へ出荷が行えなくなります。
対象地域
大阪府（全域）、兵庫県（芦屋市、尼崎市、伊丹市、西宮市）
上記地域より西の地域につきましては納期の遅延が予想されます。
また、国際便も遅延が予想されているため国内在庫がない製品の納期が一週間程度遅れる可能性がございます。
ご不便をおかけいたしますが、宜しくお願い申し上げます。